SS-31 vs FOXO4-DRI
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Elamipretide, Bendavia
A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome (September 2025) as FORZINITY, the first approved mitochondria-targeted therapeutic.
Also: FOX04-DRI, FOXO4 D-Retro-Inverso
A senolytic peptide designed to selectively eliminate senescent 'zombie' cells by disrupting the FOXO4-p53 interaction. Shows promise for restoring tissue function in aging, including kidney health restoration.
Key Comparison Insights
- SS-31 is FDA approved, while FOXO4-DRI remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to FOXO4-DRI (Animal Studies).
Detailed Comparison
| Attribute | SS-31 | FOXO4-DRI |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | SS-31 concentrates 1000-fold in mitochondria, binding to cardiolipin on the inner membrane. It optimizes electron transport chain function, reduces reactive oxygen species, and prevents cardiolipin peroxidation during cellular stress. | FOXO4-DRI is a D-retro-inverso peptide that interferes with the binding between FOXO4 and p53 proteins. In senescent cells, FOXO4 binds to p53 to prevent apoptosis, allowing these dysfunctional cells to persist. FOXO4-DRI competes for this binding, releasing p53 to trigger apoptosis specifically in senescent cells while sparing healthy cells. |
| Common Dosing | 40 mg subcutaneous daily Once daily | 2-10 mg every other day for 3 doses (one cycle) 3 doses every other day, 1-3 cycles per year |
| Administration | Subcutaneous injection or IV infusion | Subcutaneous injection (community), IV/IP in animal studies |
| Typical Duration | Variable by condition | 1 cycle = 3 doses over 5-6 days, repeat 1-3x yearly |
| Best Time to Take | Morning | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved for Barth syndrome in September 2025 under accelerated approval. Ongoing trials for dry age-related macular degeneration and primary mitochondrial myopathy. Studies show improved cardiac function, exercise capacity, and mitochondrial efficiency. | Landmark 2017 Cell study demonstrated that FOXO4-DRI restored fitness, fur density, and renal function in aged mice. Studies show improved kidney tubular cell markers, better urea/creatinine metrics, and reduced SASP (senescence-associated secretory phenotype) cytokines. A 2025 Nature Communications study provided detailed structural insights into the FOXO4-p53 interaction mechanism. Cleara Biotech is developing FOXO4-DRI for conditions including kidney disease, COPD, and osteoarthritis. |
Frequently Asked Questions: SS-31 vs FOXO4-DRI
What is the difference between SS-31 and FOXO4-DRI?
SS-31 is a anti-aging peptide that a mitochondria-targeted peptide that improves cellular energy production. fda approved for barth syndrome (september 2025) as forzinity, the first approved mitochondria-targeted therapeutic. FOXO4-DRI is a anti-aging peptide that a senolytic peptide designed to selectively eliminate senescent 'zombie' cells by disrupting the foxo4-p53 interaction. shows promise for restoring tissue function in aging, including kidney health restoration. The main differences lie in their mechanisms of action and clinical applications.
Which is better, SS-31 or FOXO4-DRI?
Neither is universally "better" - the choice depends on your specific goals. SS-31 is typically used for anti-aging purposes, while FOXO4-DRI is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can SS-31 and FOXO4-DRI be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using SS-31 and FOXO4-DRI together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of SS-31 and FOXO4-DRI is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.